Upcoming Presentation at CTAD 2024
Cognito Therapeutics, a pioneering neurotechnology firm, is set to showcase new data concerning its innovative therapy Spectris™ in treating Alzheimer’s disease. This significant event, which will take place at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, highlights Cognito’s commitment to advancing disease-modifying treatments aimed at Central Nervous System (CNS) disorders.
About Spectris™ and Its Impact
Christian Howell, the CEO of Cognito Therapeutics, expressed enthusiasm about the upcoming presentations, which underscore the promising potential of Spectris™ in preserving both brain function and structure among Alzheimer's patients. “Our recruitment strategies for the HOPE trial have enabled us to evaluate a diverse and representative group of Alzheimer's individuals,” stated Howell. He emphasized the company's continuous commitment to enhancing this non-invasive therapy for those affected by Alzheimer's.
Clinical Significance of the Findings
Ralph Kern, M.D., MHSc, Cognito's Chief Medical Officer, added that Spectris™ has demonstrated notable success by employing non-invasive auditory and visual neuromodulation techniques. The collected data show not only clinically meaningful results but also ensure the preservation of daily functions and overall brain structure.
Details of the Poster Presentations
The following poster presentations will be featured at the CTAD conference:
- Abstract Title: SPECTRIS™ Treatment Reduced Alzheimer’s Disease Dependence Score in OVERTURE I/II Phase 2 Study
Format: Poster 025
Presenter: Marwan Sabbagh, MD, Barrow Neurological Institute
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: SPECTRIS™ OVERTURE I responder analysis demonstrates consistent preservation of function and brain structure.
Number: Poster 026
Presenter: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: Clinical Trial Enrichment Strategy for Participant Selection in the Phase 3 HOPE study of Alzheimer's disease: Progress towards personalized medicine
Poster Number: LP005
Presenter: Lily Lee, Ph.D., Vice President and Head of Medical Affairs, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: Diversity amongst the Phase 3 HOPE study participants is reflective of the real-world Alzheimer’s Disease (AD) population
Poster Number: LP 099
Presenter: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
Session Name: Poster Session 3
Date/Time: Fri Nov 1 at 7:15 am - 5 pm - Abstract Title: Comparison of visually evoked steady-state oscillations between two Spectris™ eyesets
Poster Number: LP 028
Presenter: Mihaly Hajos, Ph.D., Chief Science Officer, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: Effects of sensory-evoked gamma oscillation on neurophysiological signals of visual and cognitive processing in Alzheimer’s disease
Poster Number: LP 016
Presenter: Mihaly Hajos, Ph.D., Chief Science Officer, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm
About Cognito Therapeutics
Cognito Therapeutics is a cutting-edge clinical neurotechnology company leading the way in developing disease-modifying treatments for neurodegenerative conditions. Their flagship product, Spectris™, utilizes innovative, non-invasive auditory and visual neuromodulation techniques aimed at enhancing gamma frequency brain activity. This innovative approach strives to mitigate brain atrophy and functional decline in patients with Alzheimer’s disease. The company is devoted to creating transformative, technology-driven solutions catering to the unmet needs of those suffering from CNS-related disorders. Cognito is headquartered in Cambridge, MA, where it continues to push the boundaries of neurotechnology interventions.
Frequently Asked Questions
What is the significance of the CTAD conference?
The CTAD conference is a major event focused on new scientific discoveries in Alzheimer's disease and therapies, providing a platform for researchers and companies to share significant advancements.
What is Spectris™?
Spectris™ is a non-invasive therapy developed by Cognito Therapeutics that utilizes auditory and visual stimulation to target brain activity, aiming to slow Alzheimer's progression.
Who is presenting on behalf of Cognito Therapeutics?
Several key figures from Cognito, including Christian Howell, Ralph Kern, and Marwan Sabbagh, will present data related to Spectris™.
What are some findings from the HOPE study?
The HOPE study has shown promising results with Spectris™, demonstrating consistent preservation of brain functions and structure among diverse populations.
How does Cognito Therapeutics approach Alzheimer's treatment?
Cognito Therapeutics focuses on pioneering non-invasive treatments and enhancing the quality of life for Alzheimer’s patients through innovative neurotechnology solutions.
